BioCryst Pharmaceuticals
BCRX
#4615
Rank
โ‚ฌ2.09 B
Marketcap
8,25ย โ‚ฌ
Share price
3.40%
Change (1 day)
13.70%
Change (1 year)

EPS for BioCryst Pharmaceuticals (BCRX)

EPS in 2026 (TTM): -1,51ย โ‚ฌ

According to BioCryst Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -1,52ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of 1,09ย โ‚ฌ an increase over its 2024 EPS that were of -0,38ย โ‚ฌ.

EPS history for BioCryst Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)-1,51ย โ‚ฌ-237.96%
20251,09ย โ‚ฌ-390.7%
2024-0,38ย โ‚ฌ-63.56%
2023-1,03ย โ‚ฌ-11.28%
2022-1,17ย โ‚ฌ29.13%
2021-0,90ย โ‚ฌ-4.63%
2020-0,95ย โ‚ฌ10.2%
2019-0,86ย โ‚ฌ0%
2018-0,86ย โ‚ฌ25.64%
2017-0,68ย โ‚ฌ4%
2016-0,66ย โ‚ฌ27.12%
2015-0,52ย โ‚ฌ-13.24%
2014-0,60ย โ‚ฌ23.64%
2013-0,48ย โ‚ฌ-30.38%
2012-0,69ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Gilead Sciences
GILD
6,50ย โ‚ฌ-528.90%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
3,40ย โ‚ฌ-324.64%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
-0,50ย โ‚ฌ-67.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
0,81ย โ‚ฌ-153.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
-0,47ย โ‚ฌ-68.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
-3,73ย โ‚ฌ 146.24%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
-0,39ย โ‚ฌ-74.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
-4,42ย โ‚ฌ 191.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
-0,15ย โ‚ฌ-90.17%๐Ÿ‡บ๐Ÿ‡ธ USA